ClinicalTrials.gg
RecruitingNCT07925190Updated Nov 13, 2026

A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

A Phase 3 interventional study of Mesutoclax (ICP-248) and Azacitidine (AZA) in Acute Myeloblastic Leukemia, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026Now RecruitingPrimary outcomes revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
22nd of 433
318 · median 50
Started
2026
with 55 others
Phase 3
54 of 473
25 open now
Primary completion
2029-12
later than 275 of 288 live
Registered
471st of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 22nd largest by planned enrollment of the 433 interventional ones that give a count, is one of 56 that started in 2026, is one of 54 in phase 3, reaches primary completion later than 275 of the 288 other live ones, and was the 471st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients

03

Conditions studied

  • Acute Myeloblastic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Study participants with newly diagnosed AML (excluding acute promyelocytic leukemia [APL]) confirmed per the 2022 World Health Organization (WHO) classification criteria.
  2. Age ≥65 years; or age ≥18 years and \<65 years and ineligible for intensive chemotherapy.
  3. The participant is expected to have a survival time of at least 12 weeks.
  4. For participants aged ≥65 years: Performance Status (PS) 0-2; for participants aged ≥18 years and \<65 years: ECOG PS 0-3.
  5. Participants must have adequate hepatic and renal function.
  6. Male participants must agree to refrain from unprotected sexual intercourse and sperm donation from the first dose of product through 90 days after the last dose.
  7. Female participants must meet one of the following: ; permanently sterilized; or, for females of , have a negative serum pregnancy test within 7 days prior to the first study dose. Females of reproductive potential must agree to use one highly effective method plus a supplementary barrier contraceptive method with their partner from the date of ICF signature until 180 days after the last dose.
  8. The participant is able to communicate adequately with the investigator and comply with study procedures as specified in the protocol.
  9. The participant or their legally authorized representative voluntarily provides written .

Exclusion criteria

Exclusion Criteria:

  1. Prior antitumor treatment for myeloid hematologic .
  2. Prior history of chronic myeloid leukemia (CML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).
  3. Known central nervous system (CNS) involvement of leukemia.
  4. Peripheral blood white blood cell count >25×10\^9/L prior to randomization.
  5. Active virus or virus infection.
  6. History of immunodeficiency, including positive (HIV) antibody.
  7. Use of strong or moderate /P-gp inhibitors or inducers (medications, dietary supplements, etc.) within 5 half-lives before the first dose of product.
  8. Diagnosis of another active malignant neoplasm within the past 2 years.
  9. Severe active infection requiring intravenous antimicrobial therapy.
  10. History of severe cardiovascular disease.
  11. Prior history of central nervous system disorders.
  12. History of severe bleeding diathesis.
  13. Known alcohol or substance dependence.
  14. Participants whom the investigator judges cannot adhere to the protocol due to uncontrolled medical, psychological, familial, social or geographic conditions; or participants who are unwilling or unable to follow protocol-required procedures.
  15. Pregnant or breastfeeding female participants.
  16. Malabsorption syndrome or other conditions that preclude oral administration or may interfere with drug absorption.
  17. Known to the active ingredients/ of mesutoclax tablets, venetoclax, azacitidine, or mannitol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
318 participants (estimated)

Study arms

  • Experimental
    Mesutoclax + Azacitidine

    Drug: Mesutoclax (ICP-248) · Drug: Azacitidine (AZA)

  • Active comparator
    Venetoclax + Azacitidine

    Drug: Azacitidine (AZA) · Drug: Venetoclax

Interventions

  • DrugMesutoclax (ICP-248)

    125 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.

  • 75 mg/m2, Day 1-7 or Day 1-5 and Day 8-9 of each Cycle, by injection

  • 400 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: through the study completion, approximately up to 4 years

Secondary outcomes

  1. Response rates

    Rate of complete remission with negative measurable residual disease (CRMRD-), complete remission (CR) rate, and composite complete remission (CRc) rate (CRc includes CR, CR with incomplete hematologic recovery \[CRi\] , and/or CR with partial hematological recovery (CRh))

    Time frame: within 3 cycles (each cycle is 28 days) and during study treatment, approximately up to 3 years

  2. Event free survival (EFS)

    Time frame: approximately up to 3 years

  3. Duration of CR and CRc

    Duration of CR and duration of CRc

    Time frame: during study treatment period, approximately up to 3 years

  4. EFS with molecular MRD relapse

    Measured from the date of randomization to date of treatment failure, hematological relapse, MRD relapse, or death from any cause, whichever comes first

    Time frame: approximately up to 3 years

  5. Transfusion independence rate

    Transfusion independence rate

    Time frame: approximately up to 3 years

  6. Adverse event profile per CTCAE v5.0

    Incidence, category, severity, and other characteristics of adverse events (AEs), assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: from first dose to 28 days post last dose, approximately up to 3 years

  7. Numbers of Treatment cycle

    Time frame: during study treatment period, approximately up to 3 years

  8. Treatment cycle duration

    Time frame: during study treatment period, approximately up to 3 years

  9. Days of treatment per cycle

    Time frame: during study treatment period, approximately up to 3 years

  10. Patient Reported Outcomes (PRO) by European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC-QLQ-C30)

    PROs assessed by EORTC-QLQ-C30 , changes in rating compared to baseline.

    Time frame: from first dose to 28 days post last dose, approximately up to 3 years

  11. PRO by EuroQol 5-Dimension 5-Level (EQ-5D-5L)

    PROs assessed by EQ-5D-5L, changes in rating compared to baseline.

    Time frame: from first dose to 28 days post last dose, approximately up to 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Dec 2029, 37 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 37 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 9, 2026
StartActual
Nov 3, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Jun 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • The First Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
Show 1 removed
  • The First Affiliated Hospital, Zhejiang University school of Medicine · Hangzhou, China
Nov 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Editedoverall survivalOverall Survival (OS)Time frame: through the study completion, approximately up to 4 years
Nov 13, 2026
Secondary outcomes
1 edited, 2 description edited
What changed in the outcomes
  • EditedPatient Reported Outcomes (PRO) by European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC-QLQ-C30)Time frame: from first dose to 28 days post last dose, approximately up to 3 years
  • DescriptionEFS with molecular MRD relapse: how it is measured was reworded
  • DescriptionResponse rates: how it is measured was reworded
Nov 13, 2026
Title
A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
Nov 13, 2026
Registered
First appeared on the registry
Nov 9, 2026
Show all 2 updates
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • The First Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
    Show 1 removed
    • The First Affiliated Hospital, Zhejiang University school of Medicine · Hangzhou, China
    Primary outcomes 1 edited
    What changed in the outcomes
    • Editedoverall survivalOverall Survival (OS)Time frame: through the study completion, approximately up to 4 years
    Secondary outcomes 1 edited, 2 description edited
    What changed in the outcomes
    • EditedPatient Reported Outcomes (PRO) by European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC-QLQ-C30)Time frame: from first dose to 28 days post last dose, approximately up to 3 years
    • DescriptionEFS with molecular MRD relapse: how it is measured was reworded
    • DescriptionResponse rates: how it is measured was reworded
    Title A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
    + 2 other changes: date precision and conditions
  2. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07925190
Responsible party
Sponsor
First posted
Nov 9, 2026
Start date
Nov 3, 2026
Primary completion
Dec 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Jingnan Yang
Contact
CO-Clinicaltrial@innocarepharma.com
010-66609990
Jie Jin
principal investigator · First Affiliated Hospital of Zhejiang University
Jianxiang Wang
principal investigator · Chinese Academy of Medical Sciences
Qian Jiang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion